| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.46 | 0.004 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.12 | 0.004 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.094 | 0.005 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.005 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.005 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.006 |